"Proteasome Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that inhibit the function or proteolytic action of the PROTEASOME.
| Descriptor ID |
D061988
|
| MeSH Number(s) |
D27.505.519.389.745.705
|
| Concept/Terms |
Proteasome Inhibitors- Proteasome Inhibitors
- Inhibitors, Proteasome
- Proteasome Inhibitor
- Inhibitor, Proteasome
- Proteasome Endopeptidase Complex Inhibitors
|
Below are MeSH descriptors whose meaning is more general than "Proteasome Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Proteasome Inhibitors".
This graph shows the total number of publications written about "Proteasome Inhibitors" by people in this website by year, and whether "Proteasome Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2010 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2017 | 2 | 4 | 6 |
| 2018 | 7 | 3 | 10 |
| 2019 | 1 | 1 | 2 |
| 2020 | 0 | 2 | 2 |
| 2021 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Proteasome Inhibitors" by people in Profiles.
-
A new class of a-ketoamide derivatives with potent anticancer and anti-SARS-CoV-2 activities. Eur J Med Chem. 2021 Apr 05; 215:113267.
-
NF-?B Pathway as a Potential Target for Treatment of Critical Stage COVID-19 Patients. Front Immunol. 2020; 11:598444.
-
Cardio-oncology care in the era of the coronavirus disease 2019 (COVID-19) pandemic: An International Cardio-Oncology Society (ICOS) statement. CA Cancer J Clin. 2020 11; 70(6):480-504.
-
Anticancer drugs and COVID-19 antiviral treatments in patients with cancer: What can we safely use? Eur J Cancer. 2020 09; 136:1-3.
-
Combating sars-cov-2 through lipoxins, proteasome, caveolin and nuclear factor-?b pathways in non-pregnant and pregnant populations. Cell Mol Biol (Noisy-le-grand). 2020 Jun 05; 66(3):221-229.
-
Proteasome Inhibitors as a Possible Therapy for SARS-CoV-2. Int J Mol Sci. 2020 May 20; 21(10).
-
The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges. Pharmacol Ther. 2020 09; 213:107579.
-
Non-lethal proteasome inhibition activates pro-tumorigenic pathways in multiple myeloma cells. J Cell Mol Med. 2019 12; 23(12):8010-8018.
-
Hantavirus Inhibits TRAIL-Mediated Killing of Infected Cells by Downregulating Death Receptor 5. Cell Rep. 2019 08 20; 28(8):2124-2139.e6.
-
Irreversible proteasome inhibition with carfilzomib as first line therapy in patients with newly diagnosed multiple myeloma: Early in vivo cardiovascular effects. Eur J Pharmacol. 2018 Nov 05; 838:85-90.